{"id":"NCT01181895","sponsor":"GlaxoSmithKline","briefTitle":"Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma","officialTitle":"A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistent Asthma in Adults and Adolescents Uncontrolled on Inhaled Corticosteroids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09-01","primaryCompletion":"2011-08-01","completion":"2011-08-26","firstPosted":"2010-08-13","resultsPosted":"2013-08-26","lastUpdate":"2017-11-08"},"enrollment":348,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Vilanterol","otherNames":[]},{"type":"DRUG","name":"Salmeterol Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"Placebo Inhalation Powder NDPI","otherNames":[]},{"type":"DRUG","name":"Placebo Inhalation Powder Diskus","otherNames":[]}],"arms":[{"label":"Vilanterol","type":"EXPERIMENTAL"},{"label":"Salmeterol","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.","primaryOutcome":{"measure":"Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":0.289,"sd":0.0429},{"arm":"Vilanteral 25 µg OD","deltaMin":0.359,"sd":0.0416},{"arm":"Salmeterol 50 µg BID","deltaMin":0.283,"sd":0.0419}],"pValues":[{"comp":"OG000 vs OG001","p":"0.244"},{"comp":"OG000 vs OG002","p":"0.926"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":34,"countries":["United States","Germany","Peru","Poland","Ukraine"]},"refs":{"pmids":["24928338"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":116},"commonTop":["Nasopharyngitis","Headache","Oropharyngeal pain","Upper respiratory tract infection","Pyrexia"]}}